Gastrointestinal Tract

Gastrointestinal Tract Resource Center

Welcome to the MPR Gastrointestinal Tract Resource Center, where you will find everything you need to make informed clinical decisions.

Drug Monographs

Click on the subcategory below to find drug monographs for that particular area.

News

Dr. Reddy's Launches OTC Lansoprazole

Dr. Reddy's Laboratories announced the launch of over-the-counter (OTC) Lansoprazole delayed-release capsules, the generic version of Novartis's Prevacid 24hr capsules.

Pertzye Approved for Treating Pancreatic Insufficiency

Digestive Care has received FDA approval for Pertzye (pancrelipase delayed-release capsules) for the treatment of exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF) or other conditions.

ASCO: For Chemo's Nausea, Olanzapine Beats Metoclopramide

For patients receiving highly emetogenic chemotherapy who experience breakthrough chemotherapy-induced nausea and vomiting, treatment with olanzapine (Zyprexa) is significantly better than treatment with metoclopramide.

Omeclamox-Pak Available for Treating H. pylori

Pernix Therapeutics Holdings has introduced Omeclamox-Pak, a ten-day therapy of omeprazole delayed-release capsules (20mg), clarithromycin tablets (500mg) and amoxicillin capsules (500mg) for the treatment of Helicobacter pylori (H. pylori) infection and duodenal ulcer disease (active or one-year history) to eradicate H. pylori in adult patients.

Phase 3 Trial of Vedolizumab for Crohn's Disease

Takeda announced results from the GEMINI II Phase 3 trial evaluating vedolizumab in patients with moderately to severely active Crohn's disease who have failed at least one conventional therapy, including TNFα antagonists.

RECTIV

2/13/2012

Aptalis Pharmaceutical Technologies

Pharmacological Class: Nitrate.

Active Ingredient(s): Nitroglycerin 0.4% (1.5mg/inch); oint; contains lanolin.

Indication: Treatment of moderate-to-severe pain associated with chronic anal fissure.

DIFICID

6/30/2011

Optimer Pharmaceuticals

Pharmacological Class: Macrolide antibiotic

Active Ingredient(s): Fidaxomicin 200mg; tablets.

Indication: For the treatment of Clostridium difficile-associated diarrhea.

ZUPLENZ

10/7/2010

Strativa Pharmaceuticals

Pharmacological Class: Selective 5-HT₃ receptor antagonist.

Active Ingredient(s): Ondansetron (as base) 4mg, 8mg; oral soluble film; peppermint flavor.

Indication: Prevention of nausea and vomiting associated with highly emetogenic chemotherapy, including cisplatin ≥50mg/m². Prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy. Prevention of nausea and vomiting associated with radiotherapy in patients receiving total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. Prevention of post-op nausea and/or vomiting.

Toolbox

CLINICAL CHARTS

PHARMACOLOGY NOTES

MEDICAL CALCULATORS

PATIENT INFORMATION

Acute appendicitis: Antibiotics instead of surgery?; Diagnosis and management of mononucleosis

1.00/ AAPA Category I CME Credit

This activity is taken from the May 2012 issue of JAAPA. It includes the CME articles "Acute appendicitis: Can antibiotics ever take the place of surgery?" and "Pathogenesis, diagnostic testing, and management of mononucleosis." Please note that both topics are included in the post-test.

IBD in Practice: Challenges in Diagnosis, Options in Management

1.00/ AMA PRA Category 1 Credit(s)^TM

Inflammatory bowel diseases (IBD) are complex disorders, difficult to diagnose and manage. Diagnosis is particularly challenging due to the heterogeneity of symptoms and overlap of symptoms with other IBD.